The National Cancer Institute launched the MATCH trial in August 2015 as part of the Precision Medicine Initiative announced by President Obama. Continue reading

The National Cancer Institute launched the MATCH trial in August 2015 as part of the Precision Medicine Initiative announced by President Obama. Continue reading
Researchers have identified a handful of mutations in patients with advanced prostate cancer for which therapeutics are already available, or in development. The genomes of 150 patients with metastatic (Stage 4) hormone-resistant disease were analyzed in order to develop a precision medicine framework for the treatment of advanced prostate cancer. Continue reading
Memorial Sloan Kettering has started testing the cancers of its patients for 341 cancer-related genes. It is collaborating with Quest Diagnostics to perform the analyses in an effort to identify biomarkers that can best guide appropriate therapy. This is precision medicine, and it is happening at other major cancer centers, as well… Continue reading
Using genomics to take-on advanced non-small cell lung cancer, the Southwest Oncology Group announced the start of a master protocol that will screen patients for optimal eligibility into one of five clinical trials with experimental drugs… Continue reading